Eye News and Research

Latest Eye News and Research

Oxygen Biotherapeutics 2010 first quarter net loss increases to $3 million

Oxygen Biotherapeutics, Inc., a development stage biomedical company focused on developing oxygen-rich intravenous and topical products, today announced results for the fiscal year (FY) first quarter ended July 31, 2010.

10 Sep 2010

Scientists to develop test for Mad Cow Disease detection

The eyes may or may not be windows to the soul, as the old adage goes, but scientists are reporting evidence that a peek into the eyes of cattle may become the basis for a long sought test to detect infection with the agent that causes Mad Cow Disease. That test could help prevent the disease from spreading in the food supply. A study on using the tell-tale glow given off by eyes infected with the Mad Cow agent appears in ACS' semi-monthly journal Analytical Chemistry.

9 Sep 2010

NovaBay Pharmaceuticals to deliver new data on Aganocide compounds at ICAAC Conference

NovaBay Pharmaceuticals, Inc., a clinical stage biotechnology company developing first-in-class, anti-infective compounds for the treatment and prevention of antibiotic-resistant infections, will deliver four poster presentations on its compounds at the 50th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC).

9 Sep 2010

ReVision Optics completes enrollment, initial follow up in PresbyLens Phase I clinical trial for presbyopia

ReVision Optics, a leading company in the research, development and manufacture of implantable medical devices designed to assist patients that need reading glasses, announced today that it has completed enrollment and initial follow up in Phase I of its US clinical trial and has filed for expansion. The clinical trial is for the study of the PresbyLens, recently renamed Vue+, for the improvement of near vision in patients with presbyopia, the age-related loss of near vision.

9 Sep 2010

Severe eye problems at cattle show

After nearly fifty people complained of serious eye irritations, the dairy cow pavilion at the Royal Adelaide Show has been closed down. Organizers are blaming stagnant urine for the irritations. St John Ambulance volunteers were called to the Dairy Cattle pavilion after some people reported irritation to their eyes. 30 people required treatment at the site. 20 more people reported to the emergency department of the Royal Adelaide Hospital where their eyes were washed.

8 Sep 2010

Save the Children report finds neediest children in many developing countries are overlooked

The deaths of four million of the world's poorest children over 10 years could have been avoided if governments had not turned "a blind eye" to the neediest children, said a report from Save the Children, released on Tuesday, the U.K. Press Association reports (9/6).

8 Sep 2010

Study finds increase in emergency department usage among US patients

Only 45 percent of the 354 million annual visits for acute care in the United States are made to patients' personal physicians, as Americans increasingly make busy emergency departments, specialists or outpatient care departments their first point of contact for treatment of new health problems or a flare up of a chronic condition like asthma or diabetes.

8 Sep 2010

Can-Fite BioPharma opens IND with US-FDA for CF101 Phase 3 study in Dry Eye Syndrome

Can-Fite BioPharma Ltd, a biotechnology company traded on the Tel Aviv Stock Exchange, announced today that it has opened an Investigational New Drug application (IND) with the US-FDA for a Phase 3 study of its lead drug, CF101, in patients with moderate to severe Dry Eye Syndrome.

8 Sep 2010

Promedior initiates PRM-151 Phase 2a clinical study in prevention of scarring post glaucoma filtration surgery

Promedior, Inc., a clinical stage biotechnology company developing novel therapies to treat fibrotic and inflammatory diseases, announced today that it has initiated a Phase 2a clinical study of PRM-151 to evaluate the efficacy, safety, and tolerability of PRM-151 in preventing post-surgical scarring in glaucoma patients following glaucoma filtration surgery. There currently are no approved drugs for preventing post-surgical scarring in glaucoma, and there are no approved anti-fibrotic drug therapies in the U.S. or Europe for any fibrotic disease.

7 Sep 2010

Psilocybin reduces anxiety, improves mood with advanced-stage cancer: Study

In the first human study of its kind to be published in more than 35 years, researchers found psilocybin, an hallucinogen which occurs naturally in "magic mushrooms," can safely improve the moods of patients with advanced-stage cancer and anxiety, according to an article published online today in the Archives of General Psychiatry.

7 Sep 2010

Researchers decode words from brain signals in paralyzed people

In an early step toward letting severely paralyzed people speak with their thoughts, University of Utah researchers translated brain signals into words using two grids of 16 microelectrodes implanted beneath the skull but atop the brain. "We have been able to decode spoken words using only signals from the brain with a device that has promise for long-term use in paralyzed patients who cannot now speak," says Bradley Greger, an assistant professor of bioengineering.

7 Sep 2010

Geometric pattern preference may be an early identifier of autism

Using eye-tracking methods, researchers at the University of California, San Diego School of Medicine have shown that toddlers with autism spend significantly more time visually examining dynamic geometric patterns than they do looking at social images - a viewing pattern not found in either typical or developmentally delayed toddlers.

7 Sep 2010

Microplasmin MIVI-TRUST Phase III program's positive pooled results presented at EURETINA

ThromboGenics NV, a biopharmaceutical company focused on the discovery and development of innovative treatments for eye disease, cardiovascular disease and cancer, announces that the pooled results from the successful microplasmin MIVI-TRUST Phase III program were presented today at the EURETINA (European Society of Retina Specialists) Congress in Paris, France.

6 Sep 2010

UB symposium to discuss in silico molecular design, high-throughput screening to treat diseases

Twenty-first-century pharmaceutical breakthroughs require 21st-century drug discovery tools, such as computational or in silico molecular design and high-throughput screening of effective, new compounds. That's the theme of a University at Buffalo symposium to be held Sept. 11 on "Twenty-first Century Bioscience: In Silico Methods and High-Throughput Screening," which will feature a variety of cutting-edge advances in the field developed by researchers in Western New York and throughout the US.

3 Sep 2010

Transitions Optical launches 'Healthy Sight for Life: Focus on African-American Eyes' campaign

Recognizing the increased risks African Americans face for a number of eye health issues, Transitions Optical, Inc., the leading supplier of photochromic eyeglass lenses, is launching its "Healthy Sight for Life: Focus on African-American Eyes" campaign at the National Council of Negro Women (NCNW)'s 25th annual Black Family Reunion Celebration on September 11 in Washington, D.C.

3 Sep 2010

Pennsylvania Association for the Blind offers steps to prevent all sports-related eye injuries

It's back to school time! Kids are feeling excited and maybe a little nervous. New teachers, new friends and new sports seasons. Parents are scrambling to buy back-to-school clothes and equip their children with all the sports gear they need, like helmets, pads, braces and mouth guards. Parents are taking that extra step to prevent broken bones, bruises and chipped teeth, but what are they doing to prevent possible permanent vision loss, a scratched cornea, or fractured eye sockets?

3 Sep 2010

BAP releases new guidelines on treatments for sleep disorders

Insomnia and other sleep disorders are very common, yet are not generally well understood by doctors and other health care professionals. Now the British Association for Psychopharmacology (BAP) has released up-to-the-minute guidelines in the Journal of Psychopharmacology, published by SAGE, to guide psychiatrists and physicians caring for those with sleep problems.

3 Sep 2010

Alcon to launch AcrySof IQ ReSTOR Multifocal Toric intraocular lens outside US during 2010 ESCRS meeting

Alcon, Inc., the world's leader in eye care and cataract surgery, announced its launch of the AcrySof® IQ ReSTOR® Multifocal Toric intraocular lens (IOL) outside the United States during the 2010 European Society of Cataract and Refractive Surgeons (ESCRS) annual meeting in Paris, France. This new lens is built on Alcon's industry leading AcrySof® platform and is designed to provide cataract patients that have astigmatism a surgical option that delivers quality vision at all distances with increased spectacle independence.

3 Sep 2010

Vision and eye health are key to students' classroom ability

Healthy eyes and vision are necessary for school success and an enjoyable life. Parents naturally want to help their children learn and succeed in school and enjoy life. Vision and eye health are key to students' ability to do well in the classroom, on the playground, in sports and when studying at home.

2 Sep 2010

ThromboGenics second microplasmin Phase III trial for non-surgical treatment of VMA meets primary endpoint

ThromboGenics NV, a biopharmaceutical company focused on the discovery and development of innovative treatments for eye disease, vascular disease and cancer announces that its second Phase III trial evaluating microplasmin for the non-surgical treatment of vitreomacular adhesion (VMA) has met its primary endpoint.

2 Sep 2010

Eye News and Research

Latest Eye News and Research

Oxygen Biotherapeutics 2010 first quarter net loss increases to $3 million

Scientists to develop test for Mad Cow Disease detection

NovaBay Pharmaceuticals to deliver new data on Aganocide compounds at ICAAC Conference

ReVision Optics completes enrollment, initial follow up in PresbyLens Phase I clinical trial for presbyopia

Severe eye problems at cattle show

Save the Children report finds neediest children in many developing countries are overlooked

Study finds increase in emergency department usage among US patients

Can-Fite BioPharma opens IND with US-FDA for CF101 Phase 3 study in Dry Eye Syndrome

Promedior initiates PRM-151 Phase 2a clinical study in prevention of scarring post glaucoma filtration surgery

Psilocybin reduces anxiety, improves mood with advanced-stage cancer: Study

Researchers decode words from brain signals in paralyzed people

Geometric pattern preference may be an early identifier of autism

Microplasmin MIVI-TRUST Phase III program's positive pooled results presented at EURETINA

UB symposium to discuss in silico molecular design, high-throughput screening to treat diseases

Transitions Optical launches 'Healthy Sight for Life: Focus on African-American Eyes' campaign

Pennsylvania Association for the Blind offers steps to prevent all sports-related eye injuries

BAP releases new guidelines on treatments for sleep disorders

Alcon to launch AcrySof IQ ReSTOR Multifocal Toric intraocular lens outside US during 2010 ESCRS meeting

Vision and eye health are key to students' classroom ability

ThromboGenics second microplasmin Phase III trial for non-surgical treatment of VMA meets primary endpoint

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Eye News and Research

Latest Eye News and Research

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Newsletters you may be interested in